Current treatment of non-alcoholic fatty liver disease
Ahmed, Mohamed H. and Byrne, Christopher D. (2008) Current treatment of non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 11, (3), 188-195. (doi:10.1111/j.1463-1326.2008.00926.x).
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in Western World and frequently associated with insulin resistance and overweight and occurs often with type 2 diabetes. Interestingly, NAFLD is not only regarded as a hepatic component of the metabolic syndrome but also as an independent risk factor and a marker for increase in cardiovascular disease (CVD). Significantly, NAFLD is associated with an increased risk of all-cause mortality and predicts future CVD events independent of age, sex, LDL-cholesterol and features of metabolic syndrome. Although there was initial concern about drug toxicity with NAFLD, increasing evidence suggests that commonly used drugs such as metformin and statins do not cause harm and the thiazolidinediones (TZDs) may even confer a therapeutic benefit in NAFLD. Interestingly, medical and surgical treatments of obesity show potential benefit in treating NAFLD. In this review, we have focused on the safety and therapeutic impact of TZDs, statins, metformins and obesity medications in NAFLD. The potential benefit of bariatric surgery and the role of weight loss per se in treating NAFLD are also discussed.
|Keywords:||bariatric surgery, insulin resistance, lifestyle, non-alcoholic fatty liver disease, obesity, treatment|
|Subjects:||R Medicine > RC Internal medicine|
|Divisions:||University Structure - Pre August 2011 > School of Medicine
|Date Deposited:||23 Sep 2008|
|Last Modified:||08 Jun 2012 12:36|
|Contributors:||Ahmed, Mohamed H. (Author)
Byrne, Christopher D. (Author)
|Date:||28 June 2008|
|Contact Email Address:||email@example.com|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)